One Case of Hypokalemia Caused by Abiraterone Actae Tablets

doi:10.19803/j.1672-8629.20240757

Abstract

Abstract: Objective To study limb weakness caused by abiraterone-induced hypokalemia so as to provide references for safe use of abiraterone. Methods One case of limb weakness due to abiraterone-induced hypokalemia in a 74-year-old male patient with prostate cancer was analyzed. Related literature was retrieved to explore the mechanism of action, incidence and precautions related to abiraterone-induced hypokalemia. Results The clinical pharmacist took into consideration the history of disease and medications and concluded that the patient's limb weakness might be related to hypokalemia caused by abiraterone. After symptomatic treatment and optimization of treatment plans, the patient's blood potassium level returned to normal, and the symptoms of muscle weakness improved. Conclusion Clinicians should remind patients to take prednisone regularly while they take abiraterone, and monitor the blood potassium levels regularly (at least once a month) so as to detect and manage related adverse reactions quickly and ensure the safety of patients.

Key words: Abiraterone Acetate Tablets, Hypokalemia, Weakness of Limbs, Prednisone, Adverse Drug Reaction

CLC Number:

REN Guiling, SU Changhai, WANG Xing, CHEN Gang, YAN Qiuqiang, YANG Junli. One Case of Hypokalemia Caused by Abiraterone Actae Tablets[J]. Chinese Journal of Pharmacovigilance, 2025, 22(11): 1296-1299.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240757

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I11/1296

References

[1] General Office of the National Health Commission. Prostate Cancer Diagnosis and Treatment guidelines[EB/OL]. (2022-04-03)[2025-03-10]. http://www.nhc.gov.cn/yzygj/s7659/202204/a0e67177df1f439898683e1333957c74.shtml.
[2] Chinese Clinical Oncology Guideline Committee. CSCO Guidelines for Diagnosis and Treatment of Common Malignant Tumors 2023(中国临床肿瘤学会CSCO常见恶性肿瘤诊疗指南2023)[M]中国临床肿瘤学会CSCO常见恶性肿瘤诊疗指南2023)[M]. Beijing: People's Medical Publishing House, 2023: 421-460.
[3] Chengdu Shengdi Pharmaceutical Co., Ltd. Drug Instructions for Abiraterone Tablets[EB/OL]. (2022-04-20)[2024-10-29]. https://db.yaozh.com/instruct?comprehensivesearchcontent=%E9%86%8B%E9%85%B8%E9%98%BF%E6%AF%94%E7%89%B9%E9%BE%99%E7%89%87.
[4] ZHANG XY, KONG WQ, ZHONG H, et al.Research on Adverse Event Signals of Abiraterone Based on FAERS DATABASe[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(10): 1148-1153, 1172.
[5] NKWOCHA BI, SINGH M.Abiraterone-Induced Hypokalemia: a Case Report[J]. Cureus, 2023, 15(7): e42533.
[6] YAMAMOTO Y, AKASHI Y, MINAMI T, et al.Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer[J]. Urology Case Reports, 2018, 2018: 1414395.
[7] MAO J, CHANG AK, CHIN S, et al.Polymorphic Ventricular Tach-ycardia and Cardiac Arrest from Abiraterone-Induced Hypokalemia: a Case Report[J]. Journal of Medical Case Reports, 2024, 18(1): 186.
[8] RIAD M, ALLISON JS, NAYYAL S, et al. Abiraterone-Induced Refractory Hypokalaemia and Torsades De Pointes in a Patient with Metastatic Castration-Resistant Prostate Carcinoma: a Case Report[J]. European Heart Journal-Case Reports, 2021, 5(12): ytab462.
[9] KHAN A, KNEALE B.Life Threatening Torsades De Pointes Due to Abiraterone-Induced Hypokaelemia in a Patient with Metastatic Prostate Cancer[J]. The New Zealand Medical Journal, 2016, 129(1445): 124-127.
[10] SHAFFI SK, RAVENDER R, KODAVANTI CKM, et al.Abira-terone-Associated Mineralocorticoid Excess: a Case Report[J]. Cureus, 2024, 16(1): e51757.
[11] BETSIKOS A, PASCHOU E, GELADARI V, et al.Abiraterone-Induced Secondary Hypertension: Two Wrongs Don't Make a Right[J]. Cureus, 2024, 16(5): e60299.
[12] CHENG HG, LI XW, GOU X.Selection of New Type Endocrine Drugs for Special Population with Prostate Cancer[J]. Chongqing Medicine(重庆医学), 2022, 51(16): 2866-2869.
[13] ZHANG YN, YANG HX, ZHANG L, et al.Comparative Evaluation of the Correlation between Naranjo's Assessment Scale and the Judgment Criteria of the National Center for Adverse Drug Reaction Monitoring on the Association of Drospirenone and Ethinylestradiol Tablets with Pulmonary Embolism[J]. Journal of Disease Monitor and Control(疾病监测与控制), 2023, 17(6): 430-434.
[14] ZHAO ZH, MAO Y, JIANG W, et al.A Case of Severe Hypokalemia with Tip-Twisting Ventricular Tachycardia Caused by Oral Prednisone[J]. Chinese Circulation Journal(中国循环杂志), 2008, 23(5): 323.
[15] SHPILSKY J, STEVENS J, BUBLEY G.An Up-to-Date Evaluation of Abiraterone for the Treatment of Prostate Cancer[J]. Expert Opin Pharmacother, 2021, 22(10): 1227-1234.
[16] SHEN YK, GONG RX, XIE YL, et al.Cost-Utility Analysis of Abiraterone as First-Line Treatment for Metastatic Castration-Resistant Prostate Cancer[J]. Evaluation and Analysis of Drug-Use in Hospitals(中国医院用药评价与分析), 2023, 23(11): 1363-1368.
[17] DANILA DC, MORRIS MJ, DE-BONO JS, et al.Phase ⅡMul-ticenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients with Docetaxel-Treated Castration-Resistant Prostate Cancer[J]. Journal of Clinical Oncology, 2010, 28(9): 1496-1501.
[18] LIU M, SHI YF, LE KD, et al.To Compare the Efficacy and Safety of Generic and Original Abiraterone in the Treatment of Advanced Prostate Cancer[J]. Evaluation and Analysis of Drug-Use in Hospitals(中国医院用药评价与分析), 2023, 23(6): 696-700.
[19] DECAMPS S, LIS R, EKANAYAKE P. Abiraterone-Induced Endocrinopathies[J]. Journal of Clinical Endocrinology & Metabolism, 2023, 1(2): luad039.
[20] STERNBERG CN, CASTELLANO D, DAUGAARD G, et al.Abiraterone Acetate for Patients with Metastatic Castration Resistant Prostate Cancer Progressing after Chemotherapy: Final Analysis of a Multicentre, Open-Label, Early Access Protocol Trial[J]. Lancet Oncol, 2014, 15(11): 1263-1268.
[21] RYAN CJ, SMITH MR, FIZAZI K, et al.Abiraterone Acetate Plus Prednisone Versus Placebo Plus Prednisone in Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer (COU-AA-302): Final Overall Survival Analysis of a Randomised, Double-Blind, Placebo-Controlled Phase 3 Study[J]. Lancet Oncol, 2015, 16(2): 152-160.
[22] FIZAZI K, TRAN N, FEIN L, et al.Abiraterone Plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer[J]. The New England Journal of Medicine, 2017, 377(4): 352-360.
[23] Chinese Committee for the Revision of Guidelines for the Prevention and Treatment of Hypertension, Hypertension Alliance (China), Hypertension Committee of Chinese Medical Care for International Exchange and Promotion, et al. Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 Revision)[J]. Chinese Journal of Hypertension(中华高血压杂志), 2024, 32(7): 603-700.
[24] DINSEN S, BASLUND B, KLOSE M, et al.Why Glucocorticoid Withdrawal May Sometimes Be As Dangerous as the Treatment Itself[J]. European Journal of Internal Medicine, 2013, 24(8): 714-720.